List of Excipients in Branded Drug ACETAMINOPHEN, IBUPROFEN

Generic Drugs Containing ACETAMINOPHEN, IBUPROFEN

Company	Ingredient	NDC	Excipient
GLENMARK THERAPEUTICS INC USA	acetaminophen, ibuprofen	72657-157	CROSCARMELLOSE SODIUM
GLENMARK THERAPEUTICS INC USA	acetaminophen, ibuprofen	72657-157	FERRIC OXIDE RED
GLENMARK THERAPEUTICS INC USA	acetaminophen, ibuprofen	72657-157	FERRIC OXIDE YELLOW
GLENMARK THERAPEUTICS INC USA	acetaminophen, ibuprofen	72657-157	FERROSOFERRIC OXIDE
GLENMARK THERAPEUTICS INC USA	acetaminophen, ibuprofen	72657-157	GLYCERYL DIBEHENATE
GLENMARK THERAPEUTICS INC USA	acetaminophen, ibuprofen	72657-157	HYPROMELLOSE 2910

What are the Most Frequently-Used Excipients in ACETAMINOPHEN, IBUPROFEN?

# Of NDCs	Excipient
1	CROSCARMELLOSE SODIUM
1	FERRIC OXIDE RED
1	FERRIC OXIDE YELLOW
1	FERROSOFERRIC OXIDE
1	GLYCERYL DIBEHENATE
1	HYPROMELLOSE 2910

Last updated: August 30, 2026

Executive summary: Acetaminophen and ibuprofen are mature, low-cost APIs with expired core compound protection and intense generic competition. Commercial value is shifting from the molecule to differentiated delivery, pediatric usability, rapid onset, fixed-dose combinations, reduced excipient burden, and manufacturing efficiency. Acetaminophen offers the stronger platform for pediatric, liver-conscious positioning and combination products. Ibuprofen offers greater formulation upside because of poor aqueous solubility, gastrointestinal tolerability concerns, and opportunities in soft gels, liquid-filled capsules, topical delivery, and solubilized oral systems.

Acetaminophen and Ibuprofen Excipient Strategy and Commercial Opportunities

What excipient strategies are most attractive for acetaminophen and ibuprofen?

The optimal strategy differs by API. Acetaminophen is primarily a high-dose, tablet-processing and palatability problem. Ibuprofen is primarily a solubility, dissolution, and tolerability problem.

Attribute	Acetaminophen	Ibuprofen
Primary formulation challenge	High API loading, taste, tablet strength, dissolution control	Very low aqueous solubility, dissolution rate, GI tolerability
Common oral forms	Tablets, caplets, powders, oral liquids, chewables, orally disintegrating tablets	Tablets, caplets, soft gels, oral liquids, chewables
Typical OTC adult strength	325 mg or 500 mg	200 mg
Typical pediatric liquid strength	160 mg/5 mL	100 mg/5 mL
Main excipient priorities	Compressibility, flow, taste masking, suspension stability	Wetting, solubilization, dispersion, dissolution enhancement
Differentiation potential	Moderate	High
Generic price pressure	Very high	Very high
Biosimilar exposure	None	None

Acetaminophen products can compete through convenience, dose accuracy, low-sugar or sugar-free formulations, and rapid disintegration. Ibuprofen products can support stronger technical differentiation through lipid systems, surfactants, amorphous dispersions, micronization, and alternative delivery routes.

What excipients are suitable for acetaminophen tablets and caplets?

Acetaminophen tablets typically require excipients that support high drug loading without sacrificing hardness, friability, disintegration, or dissolution.

Direct-compression systems

Common functional categories include:

• Microcrystalline cellulose for compression and tablet strength
• Lactose, mannitol, or dibasic calcium phosphate as fillers
• Croscarmellose sodium, sodium starch glycolate, or crospovidone as superdisintegrants
• Povidone or copovidone as binders
• Colloidal silicon dioxide as a glidant
• Magnesium stearate or sodium stearyl fumarate as lubricants
• Film coatings based on hypromellose, polyvinyl alcohol, polyethylene glycol, and approved colorants

A commercial formulation should minimize over-lubrication because hydrophobic lubricants can slow wetting and dissolution. The formulation should also control tablet weight variation, since acetaminophen products commonly use relatively high API loads.

Fast-dissolving and orally disintegrating tablets

Acetaminophen is suitable for orally disintegrating tablets when the dose is kept low enough to control tablet size and taste. Commercial options include:

• Crospovidone or croscarmellose sodium for rapid breakup
• Mannitol for mouthfeel and cooling sensation
• Low-substituted hydroxypropyl cellulose for porous tablet structure
• Silica-based carriers for improved powder flow
• Ion-exchange resins, cyclodextrins, or polymeric coatings for taste masking

The principal barrier is dose burden. A 500 mg acetaminophen orally disintegrating tablet may be too large or have unacceptable taste unless the product uses aggressive taste masking or a multiparticulate format.

Pediatric liquids and chewables

The U.S. pediatric acetaminophen market is anchored by the 160 mg/5 mL concentration. Products can differentiate through:

• Sugar-free syrups using glycerin, sorbitol, maltitol, or xylitol
• Suspending agents such as xanthan gum, sodium carboxymethylcellulose, or microcrystalline cellulose-carboxymethylcellulose systems
• Polysorbates or other wetting agents
• Citrate or phosphate buffers
• Preservatives where justified by the formulation and packaging system
• Flavor systems designed to suppress bitterness

Excipient selection must control sedimentation, redispersibility, viscosity, microbial robustness, and dosing accuracy. Oral syringes create a commercial opportunity because they reduce measurement errors compared with household spoons.

Sugar-free and dye-free products have practical value for pediatric, institutional, and caregiver segments. The formulation must avoid excessive polyols, which can cause gastrointestinal discomfort and limit patient acceptance.

What excipients improve ibuprofen solubility and dissolution?

Ibuprofen is a weak acid with limited aqueous solubility. Its commercial formulation opportunity is therefore greater than acetaminophen's. The objective is to increase wetting, apparent solubility, dissolution rate, or absorption consistency without creating unacceptable excipient exposure.

Conventional tablet approaches

Standard ibuprofen tablets often use:

• Microcrystalline cellulose and lactose or starch-based fillers
• Croscarmellose sodium, crospovidone, or sodium starch glycolate
• Povidone or hydroxypropyl cellulose as binders
• Colloidal silicon dioxide as a glidant
• Magnesium stearate as a lubricant

These excipients support low-cost manufacture but do not fundamentally solve ibuprofen's solubility limitations. Particle-size reduction, controlled granulation, and optimized disintegration can improve dissolution without requiring a novel excipient.

Solubilized and lipid-based systems

Higher-value options include:

• Polysorbates
• Polyoxyl castor oil derivatives
• Poloxamers
• Propylene glycol or polyethylene glycol
• Medium-chain triglycerides
• Mono- and diglycerides
• Phospholipids
• Self-emulsifying drug-delivery systems
• Soft-gel vehicles based on polyethylene glycol, glycerin, and purified water

These systems can produce faster dissolution and support liquid-filled capsules. They also create greater formulation and regulatory complexity. Compatibility with gelatin or vegetarian capsule shells, fill stability, leakage, oxidation, and precipitation during storage require extensive development work.

Amorphous dispersions and polymeric systems

Ibuprofen can be incorporated into amorphous solid dispersions using polymers such as:

• Copovidone
• Povidone
• Hypromellose
• Hypromellose acetate succinate
• Polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymers

The commercial objective is to maintain a supersaturated concentration long enough to improve dissolution and absorption. The primary technical risk is recrystallization during manufacturing or shelf life. These systems are more suitable for premium products, prescription extensions, or licensed technology than for undifferentiated 200 mg OTC tablets.

What formulations are protected by patents for acetaminophen and ibuprofen?

Core acetaminophen and ibuprofen composition-of-matter protection has expired. Current intellectual-property value generally resides in specific formulations, delivery systems, combinations, manufacturing processes, and method-of-use claims.

IP category	Acetaminophen opportunity	Ibuprofen opportunity
Composition of matter	No meaningful remaining core protection	No meaningful remaining core protection
Immediate-release tablet	Usually difficult to protect broadly	Usually difficult to protect broadly
Pediatric liquid	Suspension, taste masking, dosing systems, packaging	Suspension, solubilization, taste masking, dosing systems
Rapid-release formulation	Particle engineering, porous tablets, disintegration	Solubilized or micronized ibuprofen systems
Fixed-dose combination	Acetaminophen plus ibuprofen	Ibuprofen plus acetaminophen
Topical delivery	Limited compared with oral products	Stronger opportunity through gels, creams, patches, and sprays
Manufacturing process	Granulation, coating, particle engineering	Solid dispersion, lipid fill, micronization, crystallization control
Device and packaging	Dosing syringe, unit-dose sachet, child-resistant systems	Same, with added soft-gel and topical packaging opportunities

An enforceable patent position must claim a specific technical combination, not merely the presence of acetaminophen or ibuprofen in a conventional dosage form. Broad excipient lists are generally vulnerable to written-description, enablement, anticipation, obviousness, and design-around challenges.

When do acetaminophen and ibuprofen lose exclusivity?

Both APIs lost meaningful small-molecule exclusivity decades ago. Their commercial markets operate primarily through OTC monograph compliance, abbreviated new drug applications, approved NDAs, private-label supply, and brand recognition.

Exclusivity issue	Acetaminophen	Ibuprofen
Core API patent	Expired	Expired
Generic substitution	Extensive	Extensive
OTC monograph route	Available for compliant analgesic products	Available for compliant analgesic products
Biosimilar pathway	Not applicable	Not applicable
Current commercial moat	Brand, distribution, packaging, formulation	Brand, distribution, formulation, solubility technology
Main legal risk	Product-specific formulation or combination patents	Product-specific formulation, combination, or delivery patents

Patent expiration dates must be reviewed at the individual product and jurisdiction level. There is no single current expiration date for "acetaminophen" or "ibuprofen" because different companies hold different formulation and combination patents.

What is the FDA regulatory status and Orange Book position?

Acetaminophen and ibuprofen are established active ingredients used extensively in FDA-regulated OTC and prescription products. The FDA's OTC analgesic framework permits products that comply with the applicable monograph conditions, including active ingredient, dosage, labeling, and permitted uses (U.S. Food and Drug Administration [FDA], n.d.-a).

The Orange Book remains relevant for approved NDA and ANDA products, particularly where an NDA holder lists patents for a specific prescription or combination product. The Orange Book does not create a single patent barrier around the APIs. A generic applicant must assess:

1. Whether the reference product has listed patents.
2. Whether a Paragraph IV certification is required.
3. Whether the proposed product uses the same dosage form, strength, route, and conditions of approval.
4. Whether formulation or method-of-use claims can be avoided.
5. Whether pediatric exclusivity, orphan exclusivity, or other listed exclusivity remains.

For conventional OTC monograph products, the principal regulatory route is compliance with the monograph rather than an Orange Book-centered launch strategy. A branded or technically differentiated product may instead require an NDA, supplemental NDA, or other FDA submission depending on its claims and formulation.

The FDA Inactive Ingredient Database is a key screening tool for excipient precedent. It can identify prior use by route, dosage form, and strength, but database presence does not by itself establish approval for every formulation or patient population (FDA, n.d.-b).

Are Paragraph IV challenges relevant to acetaminophen and ibuprofen?

Paragraph IV litigation is product-specific rather than API-wide. It is most relevant where an innovator or branded company has obtained an approved NDA for:

• A fixed-dose acetaminophen-ibuprofen product
• A novel liquid or suspension
• A rapid-release or solubilized formulation
• A topical ibuprofen product
• A modified-release product
• A product supported by method-of-use claims

A generic applicant can challenge listed patents by filing a Paragraph IV certification. The commercial value of the challenge depends on the patent's claim scope, remaining term, ANDA design, 30-month stay risk, and potential for a first-filer advantage. Conventional acetaminophen and ibuprofen tablets generally have limited patent barriers because numerous suppliers already market therapeutically equivalent products.

Which companies compete in acetaminophen and ibuprofen products?

Competition spans branded OTC manufacturers, generic drug companies, private-label suppliers, contract manufacturers, and pharmacy retailers.

Representative branded and commercial entities include:

• Kenvue, associated with Tylenol acetaminophen products
• Haleon, associated with Advil ibuprofen and combination products
• Perrigo, a major OTC and private-label manufacturer
• Viatris
• Teva Pharmaceutical Industries
• Dr. Reddy's Laboratories
• Endo and legacy Par Pharmaceutical operations
• Retail private-label businesses supplied by contract manufacturers

Brand ownership and product commercialization can vary by country and transaction. The more defensible opportunities typically involve formulation technology, manufacturing scale, or channel access rather than API ownership.

What commercial opportunities exist for acetaminophen?

Pediatric and caregiver products

The strongest opportunities are dose accuracy, palatability, low-sugar positioning, dye-free products, and unit-dose packaging. A suspension with improved redispersibility and a calibrated oral syringe can command a premium over a basic liquid.

Combination analgesics

Acetaminophen is widely used in fixed-dose combinations with ibuprofen. A 500 mg acetaminophen and 200 mg ibuprofen combination has commercial appeal because it combines two established mechanisms and offers simplified dosing. The product requires careful labeling, maximum daily dose communication, and risk management for duplicate use of acetaminophen-containing medicines.

Hospital and institutional supply

Opportunities include:

• Unit-dose oral liquids
• Ready-to-administer cups
• IV acetaminophen alternatives where cost or supply is favorable
• Standardized pediatric concentrations
• Barcode-ready packaging
• Tamper-evident and child-resistant presentations

Lower-excipient and consumer-preference products

Dye-free, alcohol-free, sugar-free, vegan, and allergen-conscious formulations can support premium positioning. These claims must be substantiated by the actual formulation and labeling.

What commercial opportunities exist for ibuprofen?

Rapid-onset oral products

Micronized, solubilized, or lipid-based ibuprofen can support rapid-dissolution positioning. Claims about faster onset require appropriate clinical or pharmacokinetic substantiation and cannot rely solely on improved in vitro dissolution.

Soft gels and liquid-filled capsules

Soft gels offer a mature but commercially effective delivery system. The opportunity is strongest when the product improves swallowability, dose uniformity, or dissolution relative to conventional compressed tablets.

Pediatric liquids and chewables

Ibuprofen pediatric products can differentiate through:

• Improved taste masking
• Lower viscosity
• Easier redispersion
• Unit-dose sachets
• Dosing syringes
• Sugar-free and dye-free options

The 100 mg/5 mL concentration is widely recognized, which reduces consumer confusion but limits differentiation based solely on dose.

Topical ibuprofen

Topical gels, creams, sprays, and patches have a stronger innovation profile than standard oral tablets. Formulation variables include:

• Alcohol-water solvent systems
• Propylene glycol and other penetration enhancers
• Carbomer or cellulose-based gels
• Film-forming polymers
• Occlusive or nonocclusive patch matrices
• Controlled-release adhesive systems

Topical delivery may reduce systemic exposure in some use cases, but comparative efficacy, local tolerability, skin permeation, and regulatory status are central development requirements.

How strong are the patent estates for acetaminophen and ibuprofen?

The API patent estates are weak because the active ingredients are old and widely available. Product-level estates range from weak to moderate for ordinary tablets and from moderate to potentially stronger for complex delivery technologies.

Acetaminophen patent strength

Acetaminophen patents are most defensible when they cover:

• A defined taste-masking system
• A stable high-load tablet architecture
• A specific pediatric suspension
• A novel combination ratio
• A device-linked dosing system
• A manufacturing process that produces a measurable performance advantage

Ibuprofen patent strength

Ibuprofen patents have greater technical scope when they cover:

• A defined amorphous dispersion
• A self-emulsifying formulation
• A soft-gel fill composition
• A particle-size or polymorph profile
• A controlled-release system
• A topical permeation system
• A clinically demonstrated rapid-onset profile

Even stronger patents may face design-around risk because manufacturers can vary polymers, surfactants, particle size, capsule fill, or manufacturing conditions.

What manufacturing and IP barriers affect entry?

Manufacturing barriers are more significant for ibuprofen than for conventional acetaminophen tablets.

Manufacturing area	Acetaminophen	Ibuprofen
API sourcing	Mature and highly competitive	Mature and highly competitive
Direct compression	Feasible with established equipment	Feasible but dissolution may limit performance
Liquid manufacturing	Suspension and taste-control expertise required	Suspension or solubilization expertise required
Soft gels	Moderate barrier	Moderate to high barrier
Amorphous dispersions	Limited relevance	High process-development burden
Topical products	Limited oral-platform relevance	Semisolid, permeation, and packaging expertise required
Supply-chain risk	Low to moderate	Low to moderate
Regulatory risk	Mostly product-specific	Higher for novel delivery and excipient systems

The principal barriers are process validation, excipient qualification, stability, microbial control, packaging compatibility, and scale-up reproducibility. Novel excipients introduce a greater regulatory burden than established excipients with FDA precedent.

What generic launch risks exist for acetaminophen and ibuprofen?

Generic launch risk is low for standard tablets and higher for differentiated products.

Key risks include:

• Failure to match dissolution or suspension performance
• Excipient incompatibility
• Taste-masking failure
• Inadequate redispersibility
• Packaging-related stability loss
• Excessive lubricant effects on dissolution
• Capsule-shell interaction in soft gels
• Patent claims covering a combination or delivery system
• OTC labeling noncompliance
• Retail price erosion
• API or excipient supply interruptions

For standard acetaminophen and ibuprofen products, the commercial risk is usually price competition rather than patent litigation. For novel combinations and delivery systems, regulatory and formulation risk can exceed patent risk.

How do acetaminophen and ibuprofen compare as investment opportunities?

Acetaminophen is the lower-risk, lower-differentiation platform. It is attractive for high-volume private label, pediatric products, institutional supply, and combination products. Ibuprofen offers greater technical upside because its solubility and delivery challenges support more defensible formulation work.

Investment criterion	Acetaminophen	Ibuprofen
Market maturity	Very high	Very high
Core patent protection	None of practical relevance	None of practical relevance
Formulation innovation	Moderate	High
Manufacturing complexity	Low to moderate	Moderate to high
Premium pricing potential	Moderate	Moderate to high
Generic price erosion	Severe	Severe
Pediatric opportunity	Strong	Strong
Topical opportunity	Limited	Stronger
Combination opportunity	Strong	Strong
Best commercial model	Scale, brand, packaging, channel	Formulation technology plus channel

Key Takeaways

• Acetaminophen and ibuprofen have no meaningful remaining core API exclusivity.
• Acetaminophen formulation value is concentrated in pediatric liquids, taste masking, fast-disintegrating tablets, unit-dose packaging, and fixed-dose combinations.
• Ibuprofen offers greater formulation upside through solubilization, micronization, lipid systems, soft gels, amorphous dispersions, and topical delivery.
• FDA Inactive Ingredient Database precedent is important when selecting excipients, but it does not replace product-specific regulatory assessment.
• Paragraph IV risk is limited for ordinary generic tablets but can become material for branded combination, topical, rapid-release, and modified-release products.
• Neither product faces biosimilar competition because both are small-molecule drugs.
• Commercial success depends more on manufacturing cost, retail distribution, packaging, formulation performance, and brand positioning than on API patents.
• The strongest new-IP opportunities are specific, measurable formulation systems with demonstrated dissolution, stability, palatability, permeation, or clinical advantages.

FAQs

Can a new acetaminophen tablet obtain meaningful patent protection?

Yes, but protection must target a specific formulation, manufacturing process, combination, or delivery system. A conventional immediate-release acetaminophen tablet is difficult to protect broadly because of extensive prior art and generic competition.

Is ibuprofen a better candidate than acetaminophen for a novel excipient platform?

Generally, yes. Ibuprofen's poor aqueous solubility creates more room for technically differentiated excipient systems. The tradeoff is greater development, stability, scale-up, and regulatory complexity.

Are novel excipients necessary for a premium acetaminophen or ibuprofen product?

No. Established excipients can support meaningful differentiation through particle engineering, suspension control, taste masking, soft-gel fills, and packaging. Novel excipients may improve performance but increase regulatory burden.

Can a topical ibuprofen product avoid all systemic safety concerns?

No. Topical delivery can change exposure and tolerability, but systemic absorption, local skin reactions, labeling, and clinical performance still require evaluation.

What is the most defensible commercial product concept?

For acetaminophen, a low-sugar pediatric suspension with superior redispersibility, accurate dosing, and child-resistant unit-dose packaging is commercially practical. For ibuprofen, a solubilized rapid-dissolution soft gel or a clinically supported topical delivery system offers greater differentiation than a standard tablet.

References

1. U.S. Food and Drug Administration. (n.d.-a). Over-the-counter monograph drugs and analgesic, antipyretic, and antirheumatic products. https://www.fda.gov

2. U.S. Food and Drug Administration. (n.d.-b). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

3. U.S. Food and Drug Administration. (n.d.-c). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book

4. Electronic Code of Federal Regulations. (n.d.). 21 C.F.R. Part 343: Internal analgesic, antipyretic, and antirheumatic drug products for over-the-counter human use. https://www.ecfr.gov

5. U.S. Food and Drug Administration. (2023). Tylenol oral suspension and acetaminophen drug labeling. Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/

6. U.S. Food and Drug Administration. (2023). Ibuprofen drug labeling and approved product information. Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/

7. U.S. Pharmacopeia. (2024). United States Pharmacopeia and National Formulary. U.S. Pharmacopeial Convention.